ProQR Therapeutics N.V (NASDAQ: PRQR) established initial surge of 2.65% at $1.94, as the Stock market unbolted on Wednesday, before settling in for the price of $1.89 at the close. Taking a more long-term approach, PRQR posted a 52-week range of $1.07-$4.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its Annual Earning per share during the time was 25.70%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -14.16%. This publicly-traded company’s shares outstanding now amounts to $105.34 million, simultaneously with a float of $72.22 million. The organization now has a market capitalization sitting at $204.11 million. At the time of writing, stock’s 50-day Moving Average stood at $1.6052, while the 200-day Moving Average is $2.2791.
ProQR Therapeutics N.V (PRQR) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the ProQR Therapeutics N.V industry. ProQR Therapeutics N.V’s current insider ownership accounts for 31.36%, in contrast to 40.17% institutional ownership.
ProQR Therapeutics N.V (PRQR) Earnings and Revenue Records
ProQR Therapeutics N.V’s EPS decrease for this current 12-month fiscal period is -14.16% and is forecasted to reach -0.54 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -13.37% through the next 5 years, which can be compared against the 25.70% growth it accomplished over the previous five years trading on the market.
ProQR Therapeutics N.V (NASDAQ: PRQR) Trading Performance Indicators
Let’s observe the current performance indicators for ProQR Therapeutics N.V (PRQR). It’s Quick Ratio in the last reported quarter now stands at 4.10. The Stock has managed to achieve an average true range (ATR) of 0.11. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 10.03.
In the same vein, PRQR’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.35, a figure that is expected to reach -0.09 in the next quarter, and analysts are predicting that it will be -0.54 at the market close of one year from today.
Technical Analysis of ProQR Therapeutics N.V (PRQR)
Now, what If we examine the latest scores posted by [ProQR Therapeutics N.V, PRQR]. During the last 5-days, its volume was lower the volume of 0.47 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 58.97% While, its Average True Range was 0.1078.
Raw Stochastic average of ProQR Therapeutics N.V (PRQR) in the period of the previous 100 days is set at 54.38%, which indicates a major fall in contrast to 76.32% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 60.48% that was lower than 77.80% volatility it exhibited in the past 100-days period.
